IgM myeloma with t(4;14)(p16;q32)

Ackroyd, Sam; O’Connor, Sheila J.M.; Rawstron, Andy C.; Owen, Roger G.

doi:10.1016/j.cancergencyto.2005.04.005

Cited by 12 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the t(11;14), standard class‐switched myeloma may also be characterized by other translocations involving the IGH@ at 14q32, namely the t(4;14), t(14;16) and t(14;20) and in this context they are associated with an adverse outcome (Munshi et al , 2011). We have previously reported a patient with a t(4;14) (Ackroyd et al , 2005) and believe this current report to be the first reported case of t(14;16) in IgM MM. This case was also characterized by deletion of chromosome 13 and this, in common with standard myeloma appears to be a common abnormality in IgM MM with an overall incidence of 56% in our series (five of nine evaluable cases; Feyler et al , 2007).…”

supporting

confidence: 53%

Translocation t(14;16) in IgM multiple myeloma

et al. 2011

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 53%

Translocation t(14;16) in IgM multiple myeloma

et al. 2011

Self Cite

View full text Add to dashboard Cite

“…5,7 Recently, IgM myeloma has been found to be associated with t(11;14), which represents a translocation between the immunoglobulin heavy chain gene locus on chromosome 14 and cyclin D1 on chromosome 11; 1 case with t(4;14), an unfavorable prognostic factor, has also been reported. 8,9 …”

Section: Introductionmentioning

confidence: 99%

Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study

Reece

Vesole

Shrestha

et al. 2010

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Introduction Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively. Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes. In particular, the outcome after autologous hematopoietic stem cell transplantation (auto-HCT) has not been well defined. Patients and Methods Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period. Results The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease. Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period. Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes. Conclusion This analysis demonstrates comparable outcomes in all immunoglobulin isotypes. Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.

show abstract

“…Because of the rare incidence of IgM myeloma, most of the current evidence relies on case reports and small case series . Herein, we present the clinicopathological characteristics, outcomes and prognostic factors identified in 159 IgM myeloma cases from 20 participating centers in Europe, United States and Latin America.…”

Section: Discussionmentioning

confidence: 99%

IgM myeloma: A multicenter retrospective study of 134 patients

et al. 2017

View full text Add to dashboard Cite

IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL with 19% of patients presenting with levels >6,000 mg dL . International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.

show abstract

IgM myeloma with t(4;14)(p16;q32)

Cited by 12 publications

References 8 publications

Translocation t(14;16) in IgM multiple myeloma

Translocation t(14;16) in IgM multiple myeloma

Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study

IgM myeloma: A multicenter retrospective study of 134 patients

Contact Info

Product

Resources

About